TAK-279の安全性と、中等度から重度の活動性クローン病患者の腸の炎症を軽減できるかどうかに関する研究

基本情報

NCT ID

NCT06233461

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

268

治験依頼者名

Takeda

概要

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.

対象疾患

介入

依頼者（Sponsor）

実施施設 (13)